FTRE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
FTRE 近期報酬表現
-0.24%
Fortrea holdings inc
1.56%
同產業平均
1.17%
S&P500
與 FTRE 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
CRL | Charles river laboratories international inc | 5 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
ERAS | Erasca inc | - | 2 分 | 2 分 | 2 分 | 1 分 | |
RCKT | Rocket pharmaceuticals inc | 2 分 | 1 分 | 3 分 | 2 分 | 1 分 | |
TXG | 10x genomics inc | 2 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
XNCR | Xencor inc | 3 分 | 3 分 | 2 分 | 2 分 | 1 分 |
- CRL Charles river laboratories international inc價值 5 分趨勢 2 分波段 2 分籌碼 3 分股利 1 分查看更多
FTRE 公司資訊
Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customers' needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.